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Abstract
Hexavalent vaccines, protecting against six diseases (diphtheria, tetanus, pertussis [DTaP], poliovirus, hepatitis B virus
[HBV], and Haemophilus influenzae type b [Hib], are routinely the standard of care in Europe. The use of combined
vaccines allows the reduction of number of injections and side effects, the reduction of costs, and the increase in
adherence of the family to the vaccination schedule both in terms of the number of doses and timing. The safety
profile, efficacy and effectiveness of hexavalent vaccines have been extensively documented in infants and children
born at term, and data are accumulating in preterm infants. Hexavalent vaccines are particularly important for
preterm infants, who are at increased risk for severe forms of vaccine preventable diseases. However, immunization
delay has been commonly reported in this age group. All the three hexavalent vaccines currently marketed in Italy
can be used in preterm infants, and recent data confirm that hexavalent vaccines have a similar or lower incidence
of adverse events in preterm compared to full-term infants; this is likely due to a weaker immune system response
and reduced ability to induce an inflammatory response in preterm infants. Apnoea episodes are the adverse
events that can occur in the most severe preterm infants and / or with history of respiratory distress. The risk of
apnoea after vaccination seems to be related to a lower gestational age and a lower birth weight, supporting the
hypothesis that it represents an unspecific response of the preterm infant to different procedures. High
seroprotection rates have been reported in preterm infants vaccinated with hexavalent vaccine. However, a lower
gestational age seems to be associated with lower antibody titres against some vaccine antigens (e.g. HBV, Hib,
poliovirus serotype 1, and pertussis), regardless of the type of hexavalent vaccine used. Waiting for large
effectiveness studies, hexavalent vaccines should be administered in preterm infants according to the same
schedule recommended for infants born at term, considering their chronological age and providing an adequate
monitoring for cardio-respiratory events in the 48–72 h after vaccination, especially for infants at risk of recurrence
of apnoea.
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Introduction
In Italy, as well as in most European countries, hexava-
lent vaccines, protecting against six diseases (diphtheria,
tetanus, pertussis [DTaP], poliovirus, hepatitis B virus
[HBV], and Haemophilus influenzae type b [Hib]), are
routinely the standard of care [1–6]. Combined vaccines
allow the reduction of the number of injections and
number of side effects, the reduction of costs and the in-
crease in adherence of the family to the vaccination
schedule both in terms of the number of doses and tim-
ing [7, 8]. As a consequence, in countries which have
adopted a program based on hexavalent vaccines, the
coverage rates in the first year of life are high (from 90
to 99%) and higher than those obtained in countries that
use other multivalent vaccines as the only option or as
an alternative to hexavalent vaccination (70–90%) [8].
According to the Italian 2017–2019 National Vaccine
Prevention Plan (PNPV) schedule (Fig. 1), the primary
immunization cycle with hexavalent vaccines includes 3
doses, to be administered at 3–5-11 months of age,
followed by booster doses in preschool age (at 6 years)
with DTPa and inactivated poliovirus vaccines (DTPa-
IPV) and with dTaP-IPV in adolescents (12–18 years)
and adults, to be repeated every 10 years [9]. This strat-
egy has been associated with a dramatic reduction in the
number of cases of infectious diseases targeted by the
hexavalent vaccines in Italy [10]. Currently, three hexa-
valent vaccines are marketed in Italy, Infanrix Hexa®,
Hexyon® and Vaxelis®, which can be administered in pre-
term infants. The European Medicines Agency (EMA)
authorizes the use of the three hexavalent vaccines even
in the most severe preterm infants ( [11–13] Fig. 2).
In term infants the three hexavalent vaccines have been
proved to be not inferior to each other for immunogenicity
and safety profile, even in co-administration with anti-
pneumococcal and anti-rotavirus vaccination [11–15].
Moreover, large effectiveness studies have been performed
in several European countries (including Sweden, Denmark,
and Germany) concerning diseases such as pertussis and in-
vasive Hib [16–18]. The safety data collected in the clinical
studies on hexavalent vaccines have also demonstrated good
tolerability of these vaccines, confirmed by phase IV post-
Fig. 1 Vaccination schedule in Italy.). According to the Italian 2017–2019 National Vaccine Prevention Plan (PNPV)
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marketing surveillance studies, reporting a higher percent-
age, but not statistically significant, of fever and mild, transi-
tory, local symptoms compared to vaccines with fewer
components [11–13, 19, 20]. It was estimated that in
2018 approximately 500,000 preterm infants have
been vaccinated with Hexyon®, while a similar num-
ber of preterm infants in the same year were vacci-
nated with Infanrix Hexa® and Vaxelis® [8]. A recent
publication by a panel of Italian experts from the
Italian Society of Hygiene and Preventive Medicine,
The Italian Society of Pediatrics and the Italian Fed-
eration of Pediatrics confirmed that all the three
hexavalent vaccines can be used in preterm infants
(Tables 1 and 2), [7]. The panel underlined that no
delay in undertaking the national vaccination sched-
ule can be justified in preterm infants, as well as
reluctance in the co-administration of other vaccines,
including anti-pneumococcal vaccine and anti-
rotavirus vaccines. Once the absolute contraindica-
tions are excluded, vaccination should be executed
basing on the chronological age of the child [6, 21–
24]. This is particularly important considering that
high prevalence of sepsis [25–28], pertussis [29], and
other diseases [30, 31] have been reported in pre-
term infants.
Despite the national and international recommenda-
tions, however, several studies have shown low vac-
cination rates and delays in the majority preterm
infants [32–35]. A post-marketing surveillance study
on vaccination with Infanrix Hexa® and Hexyon® vac-
cines found that only 57.6% of preterm infants of the
Puglia in 2017 had been vaccinated by their 90th day
of life [36]. The ACTION follow-up project (Access
to Intensive Care and Neonatal Obstetrics, Access to
Obstetrical and Neonatological Intensive Care follow-
up project) evaluated preterm infants at 22–31 weeks
of EG in 5 Italian regions in 2003–2005 (Friuli-Vene-
zia-Giulia, Tuscany, Marche, Lazio, Calabria) and
showed that the delay in starting vaccination was cor-
related to a lower weight and EG at birth, to a sec-
ond hospitalization after discharge from the neonatal
intensive care unit (NICU), to maternal / paternal un-
employment, the number of children within the fam-
ily, lower socio-economic status, positive anamnesis
for cerebral palsy and ethnicity other than Caucasian
[33]. Some possible reasons of the vaccination delay
in preterm infants concern safety and efficacy of
hexavalent vaccines in these children [37–40]. Hereby,
we reviewed and summarized the recent literature re-
garding safety, efficacy and effectiveness of hexavalent
vaccines in preterm infants, which further support the
national and international recommendations.
Fig. 2 Infanrix Hexa®, Hexyon® e Vaxelis®. Summary of product characteristics as reported by EMA (European Medicine Agency). Paragraph
concerning safety in preterm infants, including those born with ≤28 weeks of gestational age and/or recent history of respiratory distress
Table 1 Sub-categories of preterm birth, based on gestational
age. From WHO. Preterm birth. Fact sheet. 2016. www.who.int/
mediacentre/factsheets/fs363/en/. (modified)
Subcategory of preterm birth Gestational age
moderate to late preterm 32 to 37 weeks
very preterm 28 to 32 weeks
extremely preterm < 28 weeks
Preterm is defined as babies born alive before 37 weeks of pregnancy
are completed
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Methods
A systematic search of the literature published from 1
January 2008 to 30 June 2019 was performed on
PubMed MEDLINE and Cochrane Library databases,
using the following Boolean expression (“infant, pre-
term” [MeSH Terms]) AND “vaccination” [MeSH terms]
AND “hevavalent vaccines” [MeSH terms]) and selecting
only articles published in English. The reference of arti-
cles retrieved by this search strategy were also examined
in order to recover any further relevant publications. A
first screening of the selected articles was carried out on
the basis of the title and the abstract. We included all
prospective or retrospective observational studies and
clinical trials regarding efficacy, effectiveness or safety
profile of hexavalent vaccines in preterm infants. Studies
that carried out a comparison between the hexavalent
vaccination in full-term and preterm infants and studies
in which hexavalent vaccines was co-administered with
other vaccination types (e.g. anti-pneumococcal, anti-
rotavirus, anti-VRS, anti-influenza) were included. The
non-pertinent articles, commentaries, letters, case series
concerning < 10 children cases, reviews, duplicates and
articles not written in English were excluded. For each
study the following data were evaluated and summarized
in the tables: year of publication, study design, gestatio-
nale age (GA) of the population, number of study
included, type of vaccination administered, outcomes
(e.g. laboratory parameters for immunogenicity, clinical
indicators for efficacy and reported adverse events for
safety), follow-up period and any study bias / limits.
Results
Initially, 101 articles were retrieved by the search strategy.
Sixteen articles regarding hexavalent vaccination in
preterm infants have been identified, of which 13 and 5
concerned safety ([39, 40, 42]; Table 3) and efficacy/effect-
iveness (Table 4), respectively. In all these studies hexava-
lent vaccines were administered according to the primary
3-dose immunization schedule, as recommended by the
Centers for Disease Control and Prevention [43]. Among
the 13 safety studies, 11 had hexavalent vaccination [39,
40, 42], as main objective, while 2 studies had, as their
main objective, other types of vaccines (anti-pneumococ-
cal and anti-rotavirus) in co-administration with hexava-
lent vaccines. In 9 out of 11 safety studies on hexavalent
vaccines, other vaccines were co-administered [39, 40, 42]
Table 2 Comparison of indications and use of the three hexavalent vaccines (from Orsi et al., 2018 [7], modified)
Infanrix Hexa® [11] Hexyon® [12] Vaxelis® [13]
Hib PRP 10 μ g
conjugated to tetanus toxoid
12 μ g







Pertussis PT PT 25 μ g
FHA 25 μ g
PRN 8 μ g
PT 25 μg
FHA 25 μg
Pertussis PT 25 μ g
FHA 25 μ g
PRN 8 μ g
PT 25 μ g
FHA 25 μ g
PT 20 μ g
FHA 20 μg
PRN3 μg
FIM type 2.3: 5 μg
Diphtheric toxoid Not less than 30 IU
* average value
Not less than 20 IU
* lower limit 95% CI
Not less than 20 IU
* lower limit 95% CI
Tetanus toxoid Not less than 40 IU Not less than 40 IU Not less than 40 IU
IPV polio Inactivated virus
Types 1, 2, 3
Inactivated virus
Types 1, 2, 3
Inactivated virus
Types 1, 2, 3
Hepatitis B
HBsAg produced in
Saccharomyces cerevisiae Hansenula polymorpha Saccharomyces
cerevisiae
Ready to use No Yes Yes No Yes Yes
Co-administration with
other vaccines included
in the national schedule
Yes Yes Yes
Minimum age Yes Yes Yes
Minimum age Not specified 6 weeks 6 weeks
Antibody persistence studies Yes Yes Yes
Effectiveness data Yes Yes Not available
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in the same vaccination session. Regarding the safety of
hexavalent vaccines in preterm infants, several studies
showed a similar or lower incidence of both local and sys-
temic adverse events in preterm compared to full-term in-
fants, probably due to the lower ability to induce an
inflammatory response in preterm infants, even when co-
administered with pneumococcal vaccine None of the ser-
ious adverse events observed in these studies were consid-
ered causally related to the vaccination. Apnoea and
alterations in reactivity in preterm infants were the most
frequently reported adverse events. Numerous studies
have shown an increase in the incidence of apnoea
episodes in preterm infants after hexavalent vaccination
[40–42]. Preterm infants who have experienced apneoa
episodes after hexavalent vaccination are generally those
in more critical clinical conditions (e.g. previous late-onset
sepsis), who required greater support through continous
positive airway pressure, and who have a positive history
for similar episodes, particularly in the 24 h prior to the
administration of the vaccination [40–42]. A lower birth
weight (< 2 kg), a lower GA (≤ 31 weeks) and chrono-
logical age (< 67 days), a positive history for similar
episodes and hospitalization for complications related to
prematurity are risk factors of recurrence of post-
vaccination apnoea [40] also at the second dose of the
vaccination schedule with variable percentage in the data-
sets (4.4–18%) [39, 40]. However, a causal relationship
between the vaccine and the appearance of cardio-
respiratory events continues to be, widely debated. The
available studies are often retrospective, with no control
group and with numbers of included children too limited
to demonstrate a statistically significant difference in the
incidence of these events in preterm infants. Furthermore,
it is difficult to distinguish apnoea related to vaccination
from those due to the clinical instability of preterm infants
due to other associated comorbidities (e.g. periventricular
hemorrhage, bronchopulmonary dysplasia or late onset
sepsis). Indeed, the only available prospective randomized
controlled trial by Carbone et al. suggests that the hexava-
lent vaccine administration is not associated with cardio-
respiratory events, showing no difference in the frequency
and severity of apnoea / bradycardia episodes in those
who had received vaccination compared to controls.
Given the potential risk of apnoea reported in several
studies, however, preterm infants still hospitalized at
2 months of life should be vaccinated before discharge
from the NICU with a clinical and respiratory moni-
toring for the 48–72 h following vaccination, particu-
larly with regard to the very low birth weight
(VLBW) preterm with a positive medical history for
cardio-respiratory events, especially in the 24 h prior
to the administration of the vaccine. If a cardio-
respiratory episode has occurred after the first vaccine
dose, the second dose should be administered in a
protected environment in those individuals at high
risk of recurrence.
Focusing on the immunogenicity of hexavalent vaccines,
high seroprotection rates have been reported in preterm
infants. However, a lower GA seems to be associated with
lower antibody titres against some vaccine antigens (eg
HBV, Hib, poliovirus serotype 1, and pertussis), regardless
of the type of hexavalent vaccine used. These data are in
agreement with previous studies in which the seroprotec-
tion rates reached 98.7–100% in preterm infants [43, 44].
Lower seroprotection rates, although still high, have been
reported with respect to pertussis and Hib (92.4 and
92.5% respectively) [44]. Although lower GA and birth
weight seem to be associated with lower antibody titres
against Hib, a booster dose of hexavalent vaccine was able
to induce a protective serological response (evaluated as
anti-PRP [anti-polyribosyl ribitol phosphate] antibody
concentration > 1 μg/mL) in 98.2% of preterm infants, sug-
gesting an adequate immunological memory in this popu-
lation [45]. On the other hand, the ability to induce an
adequate humoral response to HBV in preterm infants is
still debated. In large studies the seroprotection rates for
HBV were similar in very low birth weight (VLBW) and
low birth weight (LBW) (93.7% vs. 94.9% respectively),
However, seroprotection rates were reinforced (> 98%) by
booster vaccination for all antigens except for HBs in
VLBW children: only 88.7% of those had anti-HBs anti-
body concentrations > or = 10 mIU/mL, compared with
96.5% of LBW children (the difference was not statistically
significant) [43]. In contrast, Omenaca et al. did not ob-
serve no difference in the humoral response to HBV vac-
cination in preterm infants of lower GA and birth weight
neither after primary cycle nor after a booster dose [46].
Only one study investigated the T cell-mediated re-
sponse in preterm infants, showing comparable levels
of memory T lymphocyte response for poliovirus anti-
gens in full-term and preterm infants after hexavalent
vaccination, but the latter demonstrate several non-
specific and poliovirus-specific functional T cell limi-
tations. Moreover, although all infants developed
seroprotective poliovirus antibody titers, serotype 1 ti-
ters were lower among preterm infants (P = 0.03).
The immunogenicity of the hexavalent vaccines in co-
administration with other types of vaccines was evaluated
in several studies [47]. Effectiveness studies regarding the
use of hexavalent in preterm infants are very scarce at the
moment. Furthermore, in the available studies, a 3 + 1
schedule was used characterized, as recommended by the
Centers for Disease Control and Prevention [48], while in
some European countries, including Italy, a reduced (2 + 1)
vaccination schedule is employed. Further studies are
needed in order to define in greater detail the immunogen-
icity and effectiveness of hexavalent vaccines with reduced
schedule in preterm infants, focusing also on the potential
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differences in the subgroup of severe preterm infants (< 29
weeks of EG), in order to assess the need for additional vac-
cine doses or for early administration of booster doses.
Conclusions
Hexavalent vaccines administered to preterm infants dis-
play a good safety and immunogenicity profile even
when co-administrated with other vaccines included in
the Italian schedule. Summarizing the results of the
present review, it should be bared in mind that:. the
three hexavalent vaccines available in Italy have the same
indications and can be administered in preterm infants; •
although further studies are needed regarding their ef-
fectiveness, no delay in vaccination of clinically stable
preterm infants is justifiable; • preterm infants must be
immunized according to their chronological age, in the
same time and manner as those born at term; • severe
preterm infants who are still hospitalized at the time
when they should be vaccinated should receive the first
dose during the hospitalization, particularly in the case
of preterm infants ≤31 weeks, with a birth weight < 2.0
kg, with previous episodes of apnoea / bradycardia be-
fore vaccination and / or with severe bronchopulmonary
dysplasia, in order to provide monitoring for cardiorespi-
ratory events for the 48–72 h following vaccination; • if a
cardio-respiratory episode has occurred after the first
vaccination dose, the second dose should be adminis-
tered in a protected environment; • the specific recom-
mendation for the administration of hexavalent vaccines
in the most severe preterm infants (≤ 28 weeks) or with
a recent history of respiratory distress, as reported by
EMA, includes an additional respiratory monitoring for
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